134 related articles for article (PubMed ID: 28607505)
1. Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.
Gusella M; Pezzolo E; Modena Y; Barile C; Menon D; Crepaldi G; La Russa F; Fraccon AP; Pasini F
Pharmacogenomics J; 2018 Jan; 18(1):14-22. PubMed ID: 28607505
[TBL] [Abstract][Full Text] [Related]
2. Genetic prediction of long-term survival after neoadjuvant chemoradiation in locally advanced esophageal cancer.
Gusella M; Giacopuzzi S; Bertolaso L; Zanoni A; Pezzolo E; Modena Y; Menon D; Paganin P; Weindelmayer J; Crepaldi G; De Manzoni G; Pasini F
Pharmacogenomics J; 2017 Jun; 17(3):252-257. PubMed ID: 26927287
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
Fu JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
[TBL] [Abstract][Full Text] [Related]
5. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
7. Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer.
Rumiato E; Boldrin E; Amadori A; Saggioro D
Pharmacogenomics; 2016 May; 17(7):805-20. PubMed ID: 27181132
[TBL] [Abstract][Full Text] [Related]
8. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract][Full Text] [Related]
9. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
[TBL] [Abstract][Full Text] [Related]
11. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response.
Odenthal M; Bollschweiler E; Grimminger PP; Schröder W; Brabender J; Drebber U; Hölscher AH; Metzger R; Vallböhmer D
Int J Cancer; 2013 Nov; 133(10):2454-63. PubMed ID: 23649428
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer.
Maher SG; Gillham CM; Duggan SP; Smyth PC; Miller N; Muldoon C; O'Byrne KJ; Sheils OM; Hollywood D; Reynolds JV
Ann Surg; 2009 Nov; 250(5):729-37. PubMed ID: 19801928
[TBL] [Abstract][Full Text] [Related]
15. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract.
Höfler H; Langer R; Ott K; Keller G
Adv Exp Med Biol; 2006; 587():115-20. PubMed ID: 17163161
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review of Candidate Single-nucleotide Polymorphisms as Biomarkers for Responsiveness to Neoadjuvant Chemoradiation for Rectal Cancer.
Maring ED; Tawadros PS; Steer CJ; Lee JT
Anticancer Res; 2015 Jul; 35(7):3761-6. PubMed ID: 26124319
[TBL] [Abstract][Full Text] [Related]
19. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
20. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer.
Metzger R; Heukamp L; Drebber U; Bollschweiler E; Zander T; Hoelscher AH; Warnecke-Eberz U
Pharmacogenomics; 2010 Aug; 11(8):1105-13. PubMed ID: 20712528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
